论文部分内容阅读
目的观察长春瑞滨联合顺铂治疗晚期乳腺癌的疗效及安全性。方法 35例晚期乳腺癌患者给予长春瑞滨25 mg/m2,静脉滴注,第1天、第8天;顺铂25 mg/m2,静脉第1～3天,3周为1个周期,连用3个周期。结果 35例患者中完全缓解3例,部分缓解20例,稳定9例,进展3例,有效率为65.7%。不良反应主要为恶心、呕吐、便秘、神经毒性、骨髓抑制等,均为Ⅰ～Ⅱ度。结论长春瑞滨联合顺铂治疗晚期乳腺癌疗效显著,耐受性良好。
Objective To observe the efficacy and safety of vinorelbine plus cisplatin in the treatment of advanced breast cancer. Methods 35 cases of advanced breast cancer patients were given vinorelbine 25 mg / m2, intravenous drip on day 1, day 8; cisplatin 25 mg / m2, vein 1 to 3 days, 3 weeks for a cycle, 3 cycles. Results Among the 35 patients, complete remission was achieved in 3 cases, partial remission in 20 cases, stable in 9 cases and progression in 3 cases. The effective rate was 65.7%. Adverse reactions are mainly nausea, vomiting, constipation, neurotoxicity, bone marrow suppression, etc., are Ⅰ ~ Ⅱ degrees. Conclusion Vinorelbine combined with cisplatin in the treatment of advanced breast cancer has obvious curative effect and good tolerance.